Michela Bulfoni Michela Bulfoni

Dr. Michela Bulfoni Michela Bulfoni


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
MDmatilde degano
matilde degano
GVGiorgia Vesca
Giorgia Vesca
MBMichela Bulfoni Michela Bulfoni
Michela Bulfoni Michela Bulfoni
SZSilvia Zermano
Silvia Zermano
Stefano RestainoStefano Restaino
Stefano Restaino
GVGiuseppe Vizzielli
Giuseppe Vizzielli
This feasibility study explores the potential of salivary microRNAs (miRNAs) as non-invasive biomarkers for diagnosing endometriosis and assessing treatment response. Almost one-third of patients with endometriosis do not respond to the standard progestin treatment due to various mechanisms of progesterone resistance. MiRNAs, recognized for their stability in body fluids and role in gene regulation, may offer new diagnostic and prognostic opportunities as they are involved in the pathogenic pathways of endometriosis and progesterone resistance. We sequenced salivary miRNAs in three cohorts of patients: control women without endometriosis and patients with endometriosis who responded and did not respond to standard progestin treatment. This aims to identify the differential miRNA expression profiles associated with therapeutic response to dienogest. The preliminary results demonstrate the feasibility of miRNA sequencing from saliva and reveal distinct miRNA profiles between responders, non-responders, and controls. Key miRNAs, including mir-3168, the mir-200a family, and mir-93-5p, emerged as potential biomarkers, showing significant differential expression linked to both endometriosis presence and treatment response. Further validation of these findings in larger cohorts could pave the way for miRNA-based diagnostic and prognostic tools, potentially reducing diagnostic delays and personalizing treatment approaches for endometriosis patients, also with new target therapies.

26 July 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
APALESSANDRO PIERRI
ALESSANDRO PIERRI
GGGiulia Gagno
Giulia Gagno
AFAlessandra Lucia Fluca
Alessandra Lucia Fluca
DRDavide Radaelli
Davide Radaelli
DBDiana Bonuccelli
Diana Bonuccelli
SDStefano D'ERRICO
Stefano D'ERRICO
There is increasing evidence of cardiac involvement in COVID-19 cases, with a broad range of clinical manifestations spanning from acute life-threatening conditions such as ventricular dysrhythmias, myocarditis, acute myocardial ischemia and pulmonary thromboembolism to long-term cardiovascular sequelae. In particular, acute myocarditis represents an uncommon but frightening complication of SARS-CoV-2 infection. Even if many reports of SARS CoV-2 myocarditis are present in the literature, the majority of them lacks histological confirmation of cardiac injury. Here, we report a case of a young lady, who died suddenly a few days after testing positive for SARS-CoV-2, whose microscopic and genetics features suggested a direct cardiac involvement compatible with fulminant myocarditis.

14 September 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
Carlo TasciniCarlo Tascini
Carlo Tascini
LMLuca Montanari
Luca Montanari
FPFrancesca Patriarca
Francesca Patriarca
MBMichela Bulfoni Michela Bulfoni
Michela Bulfoni Michela Bulfoni
RFRenato Fanin
Renato Fanin
Paolo GaibaniPaolo Gaibani
Paolo Gaibani
Extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae causes difficult-to-treat bloodstream infections in patients with haematological malignancies, particularly after allogeneic haematopoietic stem cell transplantation (allo-HSCT). Carbapenems remain reliable, but their anti-anaerobic activity may aggravate intestinal dysbiosis and increase selection pressure for carbapenem resistance. Cefepime–enmetazobactam is a novel fourth-generation cephalosporin/β-lactamase inhibitor combination active against many class A ESBL-producing Enterobacterales. We describe a profoundly immunocompromised patient with acute myeloid leukaemia after allo-HSCT, grade III steroid-refractory gastrointestinal graft-versus-host disease, and intestinal colonization by an ESBL-producing K. pneumoniae isolate resistant to ceftolozane–tazobactam. The patient developed persistent bacteraemia and right pyelonephritis with small renal abscess-like lesions. Meropenem was rapidly de-escalated to cefepime–enmetazobactam, with temporary adjunctive fosfomycin and subsequently tigecycline. Blood-culture time to positivity progressively lengthened from 1.18 h to 16 h before cultures became negative. Serial cefepime therapeutic drug monitoring permitted repeated assessment of exposure and neurological toxicity risk. Whole-genome sequencing identified K. pneumoniae ST307 carrying blaCTX-M-15, blaTEM-1, blaSHV-28, and blaOXA-1, together with multiple resistance determinants and a large conjugative plasmid. This case describes the use of cefepime–enmetazobactam as part of a targeted carbapenem-sparing strategy for invasive ESBL-producing K. pneumoniae infection in a highly immunocompromised allo-HSCT recipient.